In the phase I combination trial, the combined used of UFT-folinic acid-and oxaliplatin (TEGAFOX) was tested and the recommended dose for phase II established as UFT 300 mg m−2 day−1 with leucovorin 90 mg day−1 for 14 days, and oxaliplatin 130 mg m−2 at day 1 every 3 weeks.
The COMBO-DN study that has just been completed (81) is the largest combination trial in painful DSPN and assessed whether combining standard doses of duloxetine and pregabalin is superior to increasing each drug to its maximum recommended dose in patients with incomplete pain relief.
This study was undertaken to assess baseline endometrial molecular events in the ATAC (Arimidex, tamoxifen, alone, or in combination) trial of breast cancer adjuvant therapy.
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial is a randomised, double-blind, double-dummy trial, evaluating anastrozole alone or in combination with tamoxifen compared with tamoxifen alone, as a 5-year adjuvant treatment for postmenopausal patients with early breast cancer.
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial is a randomised, double-blind trial comparing 'Arimidex' (anastrozole), alone or in combination with tamoxifen, relative to tamoxifen alone as a five year adjuvant treatment for postmenopausal women with early breast cancer.
Collectively, these results suggest that the beneficial effects observed in the combination trial for allopregnanolone-treated Npc1−/− mice are due largely to the vehicle, CD, and that allopregnanolone may provide only a small additional benefit when administered in 20% CD.
The hemorraghic phenotype persisted in all single agent trials, but the combination trial was distinct.
A combination trial of denileukin diftitox with bexarotene has shown increased activity over monotherapy.
In the clinical setting, the majority of PARP inhibitor combination trials have focused upon combining PARP inhibitors with standard of care therapies [reviewed in (Lord & Ashworth, 2012)].
In 2017 alone, 469 new combination trials were started with a combined target enrollment of 52,539 patients.
Nationwide, hundreds of combination trials are underway.
